Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) Leases (2022 - 2025)

Corvus Pharmaceuticals has reported Leases over the past 4 years, most recently at $927000.0 for Q3 2025.

  • Quarterly results put Leases at $927000.0 for Q3 2025, up 226.41% from a year ago — trailing twelve months through Sep 2025 was $927000.0 (up 226.41% YoY), and the annual figure for FY2024 was $1.2 million, up 2.44%.
  • Leases for Q3 2025 was $927000.0 at Corvus Pharmaceuticals, down from $1.0 million in the prior quarter.
  • Over the last five years, Leases for CRVS hit a ceiling of $3.0 million in Q1 2022 and a floor of $284000.0 in Q3 2024.
  • Median Leases over the past 4 years was $1.2 million (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Leases: plummeted 80.04% in 2024 and later soared 226.41% in 2025.
  • Corvus Pharmaceuticals' Leases stood at $2.2 million in 2022, then tumbled by 48.17% to $1.1 million in 2023, then increased by 2.44% to $1.2 million in 2024, then dropped by 21.24% to $927000.0 in 2025.
  • The last three reported values for Leases were $927000.0 (Q3 2025), $1.0 million (Q2 2025), and $1.1 million (Q1 2025) per Business Quant data.